Date: 14th August 2026

**To**
**Listing Compliance Department**
**BSE Limited**
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

**Scrip Code: 542248**

**Subject:** **Outcome of Board Meeting- Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, please find enclosed herewith the Un-Audited Financial Results (Standalone & Consolidated) for the quarter ended 30.06.2026 along with Limited Review Report by Statutory Auditor i.e. Keyur Shah & Associates, Chartered Accountants.

Further, the said outcome and results shall be uploaded on the website of the Company at www.deccanhealthcare.co.in

The Meeting was commenced at 01:30 P.M. and concluded at 01:40 P.M.

Kindly take this information on your record.

Thanking You

Your Faithfully,
**For Deccan Health Care Limited**
SHIKHA DAS Digitally signed by SHIKHA DAS
**Shikha Das**
**Company Secretary & Compliance Officer**
**M. No A78917**

Keyur Shah & Associates
CHARTERED ACCOUNTANTS

CA Keyur Shah
FCA, B.Com, ISA,
FAFD Certified

**Limited Review Report on unaudited standalone financial results of Deccan Health Care Limited for the Quarter ended 30th June, 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**To,**
**The Board of Directors Of,**
**Deccan Health Care Limited**

We have reviewed the accompanying the statement of unaudited Standalone financial results ("the financial statement") of **Deccan Health Care Limited** ("the Company") for the Quarter ended on **30th June, 2026.** The Financial Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down as per accounting standard prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by the independent Auditor of the Entity", issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primary to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Standalone financial results, prepared in accordance with applicable Indian Accounting standards ("Ind AS") and other recognized accounting practices and policies as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information require to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For, Keyur Shah & Associates**
**Chartered Accountants**
**F.R. No. 333288W**

KEYUR SHAH & ASSOCIATES
MEMBERSHIP NO :- 181329
CHARTERED ACCOUNTANTS

**Akhlaq Ahmad Mutavalli**
**Partner**
**M. No. 181329**
**UDIN: 26181329IPECUV9325**

**Date: - 14th August, 2026**
**Place: - Ahmedabad**

303, Shitiratna, B/s. Radisson Blu Hotel, Nr. Panchvati Circle, Ambawadi, Ahmedabad-380006. Gujarat, INDIA.
Ph. : +91 79 48999595, M. : +91 99984 30684 • Website : www.keyurshahca.com
E-mail : keyur@keyurshahca.com, ca.keyurshah2015@gmail.com

# DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, Punjagutta Hyderabad, TG - 500082

Standalone financial Results for the Quarter Ended on 30th June, 2026

Rs. in Lakhs (unless otherwise stated)

| Sr. No. | Particulars | Quarter Ended | | | Year Ended |
|---|---|---|---|---|---|
| | | 30th June, 2026 | 31st March, 2026 | 30th June, 2025 | 31st March, 2026 |
| | | Un-audited | Audited | Un-audited | Audited |
| I | **Income From Operations** | | | | |
| | a) Revenue from Operations | 2,185.61 | 2,026.49 | 2,146.95 | 8,917.10 |
| | b) Other Income | 2.57 | 0.08 | 0.62 | 0.87 |
| | **Total Income** | **2,188.18** | **2,026.57** | **2,147.57** | **8,917.97** |
| II | **Expenses** | | | | |
| | a) Cost of Materials Consumed | 2,247.34 | 1,658.80 | 1,905.21 | 6,292.45 |
| | b) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade | (745.48) | (339.63) | (361.27) | (227.54) |
| | c) Employee Benefit Expense | 120.64 | 118.88 | 136.37 | 524.53 |
| | d) Finance Costs | 15.61 | 14.33 | 1.71 | 36.61 |
| | e) Depreciation and Amortisation Expense | 38.60 | 38.11 | 40.55 | 146.36 |
| | f) Other Expenses | 478.68 | 511.30 | 394.89 | 1,839.98 |
| | **Total Expenses** | **2,155.39** | **2,001.79** | **2,117.46** | **8,612.39** |
| III | **Profit/ (Loss) Before Tax (I-II)** | **32.79** | **24.78** | **30.11** | **305.58** |
| IV | **Tax Expense** | | | | |
| | a) Current Tax | 11.74 | 5.84 | 13.17 | 88.54 |
| | b) Deferred Tax (Asset)/Liabilities | (3.58) | (3.81) | (4.31) | (12.00) |
| | **Total Tax Expense** | **8.16** | **2.03** | **8.86** | **76.54** |
| V | **Net Profit/ (Loss) After Tax for the Period (III-IV)** | **24.63** | **22.75** | **21.25** | **229.04** |
| VI | **Other Comprehensive Income/ (Loss)** | | | | |
| | a) Items that will not be reclassified to Profit & Loss (Net Of Tax) | (0.28) | (12.54) | 3.80 | (1.13) |
| | b) Items that may be reclassified to Profit & Loss (Net Of Tax) | - | - | - | - |
| | **Total Other Comprehensive Income/ (Loss)** | **(0.28)** | **(12.54)** | **3.80** | **(1.13)** |
| VII | **Total Comprehensive Income/ (Loss) for the period (V + VI)** | **24.35** | **10.21** | **25.05** | **227.91** |
| VIII | Paidup Equity Share Capital (Facevalue Rs 10 each) | 2,474.92 | 2,474.92 | 2,474.92 | 2,474.92 |
| IX | Other Equity | | | | 8,547.46 |
| X | **Earnings Per Equity Share- Basic/Diluted** | | | | |
| | **Basic** | 0.10 | 0.09 | 0.09 | 0.93 |
| | **Diluted (After conversion of warrants)** | 0.10 | 0.09 | 0.09 | 0.93 |

DECCAN HEALTHCARE LTD.

19/8/26

# DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, Punjagutta Hyderabad, TG - 500082

## Notes to Accounts -Standalone Financial Statement

[1] The above unaudited Standalone Financial Results of Deccan Health Care Limited for the Quarter Ended on 30th June, 2026 were reviewed and recommended by the Audit committee and approved by the Board of Directors, at their respective meeting held on 14th August, 2026. These results have been reviewed by the Statutory Auditors of the Company in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 (LODR) (as amended).

[2] Previous Year's /period's figures have been regrouped/rearranged/ restated/adjusted/rectified/recasted wherever considered necessary.

[3] Basis of Preparation of the Statement and Adoption of Indian Accounting Standards. The Company has adopted Indian Accounting Standard (IND AS) specified under companies (Indian) Accounting Standard Rules, 2015 [as ammended] precribed under section 133 of the companies act,2013.

[4] The Company is engaged in manufacturing of nutraceutical products. Considering the nature of Business and Financial Reporting of the Company, the Company is operating in only one Segment. Hence segment reporting is not applicable.

[5] The figure for the quarter ended 31st March, 2026 are balancing figures between the audited figures in respect of year ended on 31st March, 2026 and the nine month ended figures upto the third quarter ended on 31st December, 2025.

[6] The Status of investor's complaints during the quarter ended on 30th June, 2026 as under:-

| | |
|---|---|
| Complaints pending at the beginning of the period | Nil |
| Complaints received during the period | Nil |
| Complaints disposed during the period | Nil |
| Complaints resolved at the end of the period | Nil |

For, Deccan Health Care Limited

DECCAN HEALTHCARE LTD.

14/8/26

Mohak Gupta
Whole-time Director
(DIN: 03534904)

Date : 14th August, 2026
Place : Hyderabad

Keyur Shah & Associates
CHARTERED ACCOUNTANTS
CA Keyur Shah
FCA, B.Com, ISA,
FAFD Certified

**Independent Auditor's Limited Review Report on the Quarterly Unaudited Consolidated Financial Results of the Deccan Health Care Limited, for the Quarter ended 30th June, 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**To,**
**The Board of Directors of,**
**Deccan Health Care Limited**

We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Deccan Health Care Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the Quarter ended **30th June, 2026** ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

KEYUR SHAH & ASSOCIATES
MEMBERSHIP NO :- 187229
CHARTERED ACCOUNTANTS

The Statement includes the results of the following entities:

**List of Subsidiaries:**

1. Beyoungstore Private Limited

Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the statement provided by the Management related to subsidiary, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard ("Ind AS") and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The accompanying Statement includes the unaudited interim financial results/ financial information in respect of:

One subsidiary, whose unaudited interim financial results reflect total income of ₹ 259.44 Lakhs, total profit after tax of ₹ 4.50 Lakhs and total comprehensive income of ₹ 4.50 Lakhs for the quarter ended 30th June, 2026, as considered in the Statement.

These interim financial results have been approved and furnished to us by the Management, and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such unaudited interim financial result.

Our conclusion on the statement is not modified in respect of these matters

**For, Keyur Shah & Associates**
**Chartered Accountants**
**F.R.No. 333288W**

KEYUR SHAH & ASSOCIATES
MEMBERSHIP NO :- 181329
CA
CHARTERED ACCOUNTANTS

**Akhlaq Ahmad Mutavalli**
**Partner**
**M. No. 181329**
**UDIN: 26181329QOJKSU9515**

**Date: 14th August, 2026**
**Place: - Ahmedabad**

# DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarakapuri Colony, Somajiguda, Hyderabad, Telangana -500082

**Consolidated financial Results for the Quarter Ended on 30th June, 2026**

| Sr. No. | Particulars | Quarter Ended | | | Year Ended |
|---|---|---|---|---|---|
| | | Amounts in Lakhs (unless otherwise stated) | | | |
| | | 30th June,2026 | 31st March, 2026 | 30th June,2025 | 31st March, 2026 |
| | | Unaudited | Audited | Unaudited | Audited |
| I | **Income From Operations** | | | | |
| | a) Revenue from Operations | 2,206.91 | 2,097.52 | 2,214.02 | 8,190.48 |
| | b) Other Income | 2.57 | 0.08 | 0.62 | 0.87 |
| | **Total Income** | **2,209.48** | **2,097.60** | **2,214.64** | **8,191.35** |
| II | **Expenses** | | | | |
| | a) Cost of Materials Consumed | 2,265.81 | 1,581.85 | 1,911.56 | 5,265.76 |
| | b) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade | (745.48) | (339.63) | (361.27) | (227.54) |
| | c) Employee Benefit Expense | 125.80 | 121.19 | 138.68 | 533.77 |
| | d) Finance Costs | 15.62 | 14.33 | 1.72 | 36.63 |
| | e) Depreciation and Amortisation Expense | 38.60 | 38.11 | 40.55 | 146.36 |
| | f) Other Expenses | 470.28 | 645.05 | 450.01 | 2,109.80 |
| | **Total Expenses** | **2,170.63** | **2,060.90** | **2,181.25** | **7,864.78** |
| III | **Profit/ (Loss) Before Tax (I-II)** | **38.85** | **36.70** | **33.39** | **326.57** |
| IV | **Tax Expense** | | | | |
| | a) Current Tax | 13.32 | 7.11 | 13.99 | 89.81 |
| | b) Deferred Tax (Asset)/Liabilities | (3.58) | (3.81) | (4.31) | (12.00) |
| | **Total Tax Expense** | **9.74** | **3.30** | **9.68** | **77.81** |
| V | **Net Profit/ (Loss) After Tax for the Period (III-IV)** | **29.11** | **33.40** | **23.71** | **248.76** |
| VI | **Other Comprehensive Income/ (Loss)** | | | | |
| | a) Items that will not be reclassified to Profit & Loss (Net of Tax) | (0.28) | (12.54) | 3.80 | (1.13) |
| | b) Items that may be reclassified to Profit & Loss (Net of Tax) | - | - | - | - |
| | **Total Other Comprehensive Income/ (Loss)** | **(0.28)** | **(12.54)** | **3.80** | **(1.13)** |
| VII | **Total Comprehensive Income/ (Loss) for the period (V + VI)** | **28.83** | **20.86** | **27.51** | **247.63** |
| VIII | **Paidup Equity Share Capital (Facevalue Rs 10 each)** | **2,474.92** | **2,474.92** | **2,474.92** | **2,474.92** |
| IX | **Other Equity** | | | | **8,551.09** |
| X | **Earnings Per Equity Share- Basic/Diluted** | | | | |
| | **Basic** | 0.12 | 0.14 | 0.10 | 1.01 |
| | **Diluted (After Conversion of warrants)** | 0.12 | 0.14 | 0.10 | 1.01 |

DECCAN HEALTH CARE LTD

14/8/26

# DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarakapuri Colony, Somajiguda, Hyderabad, Telangana -500082


## Notes to Accounts -Consolidated Financial Statement

[1] The above unaudited consolidated financial results for the quarter ended 30th June, 2026 have been prepared by the Company in accordance with regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the board of directors in their meeting held on 14th August, 2026. A Limited review of the above results has been carried out by the statutory auditors of the company.

[2] Previous Year's /period's figures have been regrouped/rearranged/ restated/adjusted/rectified/recasted wherever considered necessary.

[3] Basis of Preparation of the Statement and Adoption of Indian Accounting Standards. The Company has adopted Indian Accounting Standard (IND AS) specified under companies (Indian) Accounting Standard Rules, 2015 [as ammended ] precribed under section 133 of the companies act,2013.

[4] The figure for the quarter ended 31st March, 2026 are balancing figures between the audited figures in respect of year ended on 31st March, 2026 and the nine month ended figures upto the third quarter ended on 31st December, 2025.

[5] The Company is engaged in manufacturing of nutraceutical products. Considering the nature of Business and Financial Reporting of the Company, the Company is operating in only one Segment. Hence segment reporting is not applicable.

[6] The Status of investor's complaints during the quarter ended on 30th June, 2026 as under:-

| | |
|---|---|
| Complaints pending at the beginning of the period | NIL |
| Complaints received during the period | NIL |
| Complaints disposed during the period | NIL |
| Complaints resolved at the end of the period | NIL |

For, Deccan Health Care Limited

DECCAN HEALTHCARE LTD.

14/8/26

Mohak Gupta
Whole-time director
(DIN: 03534904)

**Date : 14th August, 2026**
**Place : Hyderabad**